Anh T. Le

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer1,067 trích dẫn
Clinical Cancer Research · 2012 · DOI

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial822 trích dẫn
The Lancet Oncology · 2015 · DOI

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer607 trích dẫn
Nature Medicine · 2013 · DOI

Identifying and Targeting <i>ROS1</i> Gene Fusions in Non–Small Cell Lung Cancer472 trích dẫn
Clinical Cancer Research · 2012 · DOI

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer461 trích dẫn
Nature Medicine · 2018 · DOI

An Oncogenic <i>NTRK</i> Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101390 trích dẫn
Cancer Discovery · 2015 · DOI

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer251 trích dẫn
Clinical Cancer Research · 2018 · DOI

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib204 trích dẫn
Journal of Thoracic Oncology · 2018 · DOI

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study164 trích dẫn
The Lancet · 2023 · DOI

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer154 trích dẫn
Clinical Cancer Research · 2018 · DOI